Class Action Lawsuit Filed Against Atara Biotherapeutics by Pomerantz Law Firm
On April 30, 2026, Pomerantz LLP announced the instigation of a class action lawsuit targeting Atara Biotherapeutics, Inc. (NASDAQ: ATRA) and several of its executives. This action, filed in the United States District Court for the Central District of California under docket number 26-cv-03083, comes as a response to significant allegations against Atara regarding violations of federal securities laws.
This class action aims to represent all individuals and entities, excluding the defendants, who acquired Atara securities between May 20, 2024, and January 9, 2026—collectively referred to as the "Class Period." The lawsuit seeks to recover damages allegedly incurred by investors due to mismanaged disclosures by the company and its executives, based on accusations of misleading statements concerning the firm’s operations and commercial forecasts.
For investors who purchased Atara's securities during this specified timeframe, the deadline for requesting to be designated as Lead Plaintiff in the case is May 22, 2026. Interested parties can obtain a copy of the complaint at the Pomerantz Law Firm's website. To address inquiries regarding this lawsuit, potential claimants are encouraged to reach out to attorney Danielle Peyton via email or phone.
Atara Biotherapeutics is focused on developing innovative therapies for solid tumors, hematologic malignancies, and autoimmune disorders, primarily in the United States and the United Kingdom. Its leading product candidate is tabelecleucel, also called tab-cel or EBVALLO, formulated to treat Epstein-Barr virus positive post-transplant lymphoproliferative diseases (EBV+ PTLD).
In a strategic partnership with Pierre Fabre Médicament, Atara has relied substantially on milestone payments linked to the progress of tabelecleucel. These dealings are crucial for funding its operational requirements as the company strives for regulatory approval of its product.
In May 2024, Atara announced it submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel purportedly supported by positive outcomes from its Phase 3 ALLELE study, which assessed the drug for treating EBV+ PTLD.
However, the claims within the complaint assert that the company’s executives disseminated false and misleading information related to its business and future prospects, alleging that:
1. Manufacturing challenges and flaws intrinsic to the ALLELE study were likely to hinder FDA approval of the tabelecleucel BLA.
2. These regulatory uncertainties placed Atara at increased risk of scrutiny, jeopardizing its clinical trials.
3. The accumulated implications were bound to detrimentally affect Atara's financial health and business operations.
The downward trajectory of Atara's stock began on January 16, 2025, when the company disclosed receiving a Complete Response Letter (CRL) from the FDA, signaling that its BLA could not be approved in its current state due to observations made during a pre-licensing inspection of a third-party manufacturing facility. Consequently, the stock plummeted by 40.5%, dropping to $7.83 per share on that date.
Further complicating matters, on January 21, 2025, Atara announced that the FDA imposed a clinical hold on its existing Investigational New Drug (IND) applications due to unresolved good manufacturing practice (GMP) compliance issues identified in the previously mentioned inspection, causing a further decrease in share price by 7.91% to close at $6.05 per share.
The situation deteriorated again on January 12, 2026, when another CRL was issued regarding the tabelecleucel BLA, indicating that the submitted evidence was inadequate for demonstrating effectiveness for regulatory approval, which caused a staggering drop of approximately 57% in Atara’s stock price, descending to $5.88 per share.
Pomerantz LLP, distinguished for its effectiveness in corporate, securities, and antitrust class actions, continues to serve as an advocate for victims of securities fraud as established by its founder, Abraham L. Pomerantz, renowned for pioneering securities class action litigation. Over its diverse history of more than 85 years, the firm has successfully secured billions in awards for those affected by corporate misconduct.
For further details regarding the class action or inquiries on how to participate, interested individuals can visit the Pomerantz Law Firm’s official website or contact their offices directly.
This class action aims to represent all individuals and entities, excluding the defendants, who acquired Atara securities between May 20, 2024, and January 9, 2026—collectively referred to as the "Class Period." The lawsuit seeks to recover damages allegedly incurred by investors due to mismanaged disclosures by the company and its executives, based on accusations of misleading statements concerning the firm’s operations and commercial forecasts.
For investors who purchased Atara's securities during this specified timeframe, the deadline for requesting to be designated as Lead Plaintiff in the case is May 22, 2026. Interested parties can obtain a copy of the complaint at the Pomerantz Law Firm's website. To address inquiries regarding this lawsuit, potential claimants are encouraged to reach out to attorney Danielle Peyton via email or phone.
Atara Biotherapeutics is focused on developing innovative therapies for solid tumors, hematologic malignancies, and autoimmune disorders, primarily in the United States and the United Kingdom. Its leading product candidate is tabelecleucel, also called tab-cel or EBVALLO, formulated to treat Epstein-Barr virus positive post-transplant lymphoproliferative diseases (EBV+ PTLD).
In a strategic partnership with Pierre Fabre Médicament, Atara has relied substantially on milestone payments linked to the progress of tabelecleucel. These dealings are crucial for funding its operational requirements as the company strives for regulatory approval of its product.
In May 2024, Atara announced it submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel purportedly supported by positive outcomes from its Phase 3 ALLELE study, which assessed the drug for treating EBV+ PTLD.
However, the claims within the complaint assert that the company’s executives disseminated false and misleading information related to its business and future prospects, alleging that:
1. Manufacturing challenges and flaws intrinsic to the ALLELE study were likely to hinder FDA approval of the tabelecleucel BLA.
2. These regulatory uncertainties placed Atara at increased risk of scrutiny, jeopardizing its clinical trials.
3. The accumulated implications were bound to detrimentally affect Atara's financial health and business operations.
The downward trajectory of Atara's stock began on January 16, 2025, when the company disclosed receiving a Complete Response Letter (CRL) from the FDA, signaling that its BLA could not be approved in its current state due to observations made during a pre-licensing inspection of a third-party manufacturing facility. Consequently, the stock plummeted by 40.5%, dropping to $7.83 per share on that date.
Further complicating matters, on January 21, 2025, Atara announced that the FDA imposed a clinical hold on its existing Investigational New Drug (IND) applications due to unresolved good manufacturing practice (GMP) compliance issues identified in the previously mentioned inspection, causing a further decrease in share price by 7.91% to close at $6.05 per share.
The situation deteriorated again on January 12, 2026, when another CRL was issued regarding the tabelecleucel BLA, indicating that the submitted evidence was inadequate for demonstrating effectiveness for regulatory approval, which caused a staggering drop of approximately 57% in Atara’s stock price, descending to $5.88 per share.
Pomerantz LLP, distinguished for its effectiveness in corporate, securities, and antitrust class actions, continues to serve as an advocate for victims of securities fraud as established by its founder, Abraham L. Pomerantz, renowned for pioneering securities class action litigation. Over its diverse history of more than 85 years, the firm has successfully secured billions in awards for those affected by corporate misconduct.
For further details regarding the class action or inquiries on how to participate, interested individuals can visit the Pomerantz Law Firm’s official website or contact their offices directly.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.